CMRX Insider Trading

Insider Ownership Percentage: 13.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $92,241.70

Chimerix Insider Trading History Chart

This chart shows the insider buying and selling history at Chimerix by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$50k$0$50kTotal Insider BuyingTotal Insider Selling

Chimerix Share Price & Price History

Current Price: $8.51
Price Change: Price Decrease of -0.005 (-0.06%)
As of 04/1/2025 03:22 PM ET

This chart shows the closing price history over time for CMRX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$8.51Closing price on 03/31/25:

SEC Filings (Institutional Ownership Changes) for Chimerix (NASDAQ:CMRX)

45.42% of Chimerix stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CMRX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$116Mbought$23MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100M-$50M$0$50M$100MTotal InflowsTotal Outflows
Chimerix logo
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Read More on Chimerix

Today's Range

Now: $8.51
Low: $8.50
High: $8.51

50 Day Range

MA: $5.94
Low: $3.78
High: $8.52

52 Week Range

Now: $8.51
Low: $0.75
High: $8.53

Volume

1,244,480 shs

Average Volume

2,126,034 shs

Market Capitalization

$797.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Who are the company insiders with the largest holdings of Chimerix?

Chimerix's top insider investors include:
  1. Michael T Andriole (CEO)
  2. Michael T Andriole (CFO)
  3. Michael Albert Alrutz (SVP)
  4. Michelle Laspaluto (CFO)
  5. Allen S Melemed (Insider)
  6. David Jakeman (VP)
  7. Fred A Middleton (Director)
  8. Martha J Demski (Director)
  9. Robert J Meyer (Director)
Learn More about top insider investors at Chimerix.